An executive with decades of experience in the health care industry, Ari Kellen has active roles with several healthcare tech companies. For example, Ari Kellen sits on the board of directors for the French ultrasound equipment developer Theraclion.
One of Theraclion’s signature products is Sonovein. Launched as an R&D project in 2019, Sonovein is the world’s first and only robotic platform that uses non-invasive ultrasound to treat varicose veins.
In April of 2023, Theraclion announced that the FDA approved its Investigational Device Exemption (IDE) application to initiate a multi-center pivotal study VEINRESET for the treatment of primary insufficiency of great saphenous veins with Sonovein. And in May 2023, Theraclion announced the signing of a strategic agreement with its long-term partner Furui, the launch of a financing with various investors for a total amount of up to 15M€, which would allow it to finance the deployment of its strategy over 3 years, and the appointment of a new CEO.
